Lisa La on the Next 5 Years in Multiple Myeloma Research

Video

The clinical researcher spoke about what she hopes will occur in multiple myeloma research over the next 5 years.

In an interview with CancerNetwork®, Lisa La, director of clinical research in the Center for Cancer Care at White Plains Hospital, discussed what she hopes will occur in multiple myeloma research over the next 5 years.

Transcription:

Hopefully we find a cure for myeloma. The director that I worked with at Sinai, I remember interviewing someone with him and the coordinator asked him specifically, “What is your goal in myeloma? You’re doing all these things. You've dedicated the last 20, 30 years of your life to myeloma into your patients. Your patients have your cell phone number, they call you at your house.” And he said, “To find a cure, as simple as that, why else would I dedicate my life to myeloma?”

And that resonated with me, you know, and I think that his passion and along with other oncologists that I've met along the way, who have focused on myeloma really, really have a passion and hoping to find a cure. And that's what I hope, that we are one step closer each year, and hopefully in 5 years we would have some sort of cure. But patients are living a lot longer, again, from 10 years ago when I started to now, but you know, we have to keep pushing the boundaries to see what else we can do.

Recent Videos
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Sonia Jain, PhD, stated that depatuxizumab mafodotin, ABBV-221, and ABBV-321 were 3 of the most prominent ADCs in EGFR-amplified glioblastoma.
Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.
Combining daratumumab with other agents is one strategy that investigators are exploring in the smoldering multiple myeloma field.
Related Content